Buclizine
As of the edition of 20 October 2026, Buclizine is a small molecule: marketed, first approved in 1982 (US); acts on HRH1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Bucladin-S
- First approved
- 1 January 1982 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- AstraZeneca
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Acquired holder | 2003 to now |
| Stuart Therapeutics | Earlier holder |